temozolomide has been researched along with Myelodysplastic Syndromes in 11 studies
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4." | 5.35 | Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. ( Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S, 2008) |
| " We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)." | 4.82 | Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. ( Chang, MC; Chiang, MF; Hsieh, RK; Su, YW, 2005) |
| "Seven patients (4 men; 3 women) ages 34-69 years (median 44), with gliomas (3 Grade 2; 4 Grade 3) were treated with surgery, all but one with involved-field radiotherapy and all with alkylator-based chemotherapy (temozolomide; 6 patients, nitrosoureas; 5 patients, both agents; 5 patients)." | 3.75 | Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. ( Chamberlain, MC; Raizer, J, 2009) |
| " Commenced 15 years ago, PRRT is now becoming established as first- and second-line therapy for gastroentero pancreatic neuroendocrine tumors (GEPNETs), and early treatment minimizes myelotoxicity, which is the most significant potential adverse event following PRRT." | 2.53 | Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. ( Kesavan, M; Turner, JH, 2016) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4." | 1.35 | Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. ( Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S, 2008) |
| "Temozolomide is an effective alkylating agent that is increasingly used for the treatment of pediatric brain tumors." | 1.35 | Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report. ( Auger, N; Bhangoo, R; Da Costa, L; Dufour, C; Grill, J; Jullien, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brandwein, JM | 1 |
| Kassis, J | 1 |
| Leber, B | 1 |
| Hogge, D | 1 |
| Howson-Jan, K | 1 |
| Minden, MD | 1 |
| Galarneau, A | 1 |
| Pouliot, JF | 1 |
| Rashidi, A | 1 |
| Sorscher, SM | 1 |
| Kesavan, M | 1 |
| Turner, JH | 1 |
| Kushner, BH | 1 |
| Laquaglia, MP | 1 |
| Kramer, K | 1 |
| Modak, S | 1 |
| Cheung, NK | 1 |
| Dufour, C | 1 |
| Da Costa, L | 1 |
| Auger, N | 1 |
| Jullien, M | 1 |
| Bhangoo, R | 1 |
| Grill, J | 1 |
| Chamberlain, MC | 1 |
| Raizer, J | 1 |
| Nishikawa, R | 1 |
| Kim, SJ | 1 |
| Park, TS | 1 |
| Lee, ST | 1 |
| Song, J | 1 |
| Suh, B | 1 |
| Kim, SH | 1 |
| Jang, SJ | 1 |
| Lee, CH | 1 |
| Choi, JR | 1 |
| Seiter, K | 1 |
| Liu, D | 1 |
| Siddiqui, AD | 1 |
| Lerner, R | 1 |
| Nelson, J | 1 |
| Ahmed, T | 1 |
| Su, YW | 1 |
| Chang, MC | 1 |
| Chiang, MF | 1 |
| Hsieh, RK | 1 |
| Noronha, V | 1 |
| Berliner, N | 1 |
| Ballen, KK | 1 |
| Lacy, J | 1 |
| Kracher, J | 1 |
| Baehring, J | 1 |
| Henson, JW | 1 |
4 reviews available for temozolomide and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; N | 2016 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes, | 2005 |
Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.
Topics: Aged; Breast Neoplasms; Dacarbazine; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndr | 2006 |
2 trials available for temozolomide and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survi | 2014 |
Evaluation of temozolomide in patients with myelodysplastic syndrome.
Topics: Aged; Anemia; Antineoplastic Agents, Alkylating; Cardiomyopathies; Dacarbazine; Drug Evaluation; Fem | 2004 |
5 other studies available for temozolomide and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 2015 |
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.
Topics: Adolescent; Adult; Cell Transformation, Neoplastic; Child; Combined Modality Therapy; Dacarbazine; F | 2008 |
Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Cranial Irradi | 2008 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2009 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; G | 2009 |